Withdrawal of warfarin after deep vein thrombosis: Effects of a low fixed dose on rebound thrombin generation

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 5, 1999, Pages 291-295

  Ascani, A ^a   Iorio, A ^a   Agnelli, G ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Deep vein thrombosis; Thrombin; Thrombosis; Venous thromboembolism; Warfarin

Indexed keywords

BLOOD CLOTTING FACTOR 7; HEPARIN; PEPTIDE FRAGMENT; PROTEIN C; THROMBIN; WARFARIN;

ADOLESCENT; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG WITHDRAWAL; ENZYME RELEASE; FEMALE; HUMAN; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; REBOUND; RECURRENT DISEASE; TECHNIQUE;

EID: 0032776289     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199907000-00011     Document Type: Article

References (16)

1. 1. Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, et al. Warfarin sodium versus low dose heparin in the long term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-858.
2. 2. Hull R, Delmore T, Carter C, Hirsh J, Genton E, Gent M, et al. Adjusted subcutaneous heparin versus warfarin sodium in long term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-194.
3. 3. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. Circulation 1996; 93: 2212-2245.
4. 4. O'Sullivan EF. Duration of anticoagulant therapy in venous thromboembolism. Med J Aust 1972; 2: 1104-1107.
5. 5. Holmgren K, Andersson G, Fagrell B, Johnsson H, Ljungberg B, Nilsson E, et al. One month versus six month therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand 1985; 218: 279-284.
6. 6. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep vein thrombosis and pulmonary embolism. Lancet 1992; 340: 873-876.
7. 7. Levine MN, Hirsh J, Gent M, Turpic AG, Weitz J, Ginsberg J, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-611.
8. 8. Schulman S, Rhedin S, Lindmarker P, Carlsson A, Larfars G, Nicol P, et al., and the Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-1665.
9. 9. Poller L, Thomson J. Evidence of rebound hypercoagulability after stopping anticoagulants. Lancet 1964; ii: 62-64.
10. 10. Van Cleve R. The rebound phenomenon-fact or fancy? Experience with discontinuation of long term anticoagulation therapy after myocardial infarction. Circulation 1965; 32: 878-880.
11. 11. Harenberg J, Haas R, Zimmermann R. Plasma hypercoagulability after termination of oral anticoagulants. Thromb Res 1983; 29: 627-633.
12. 12. Palareti G, Legnani C, Guazzaloca G, Frascaro M, Grauso F, De Rosa F, et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants. A prospective study. Thromb Haemost 1994; 72: 222-226.
13. 13. Genewein U, Haeberli A, Straub PW, Beer JH. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol 1996; 92: 479-485.
14. 14. Michaelis L, Beamish RE. Relapse of thromboembolic disease after discontinuation of anticoagulant therapy: a comparison of the incidence after abrupt and after gradual termination treatment. Am J Cardiol 1967; 20: 670-673.
15. 15. SAS Institute Inc. SAS/STAT User's Guide. Version 6, 4th Edition. Cary, NC: SAS Institute Inc.; 1989.
16. 16. Tripodi A, Cattaneo M, Molteni A, Cesana BM, Mannucci PM. Changes of prothrombin fragment 1+2 (F1+2) as a function of increasing intensity of oral anticoagulation. Thromb Haemost 1998; 79: 571-573.